American Heart Association Scientific Sessions 2021
Abstract Submission Guidelines
Sessions – ReSS - QCOR

NOVEMBER 13-15 / BOSTON, MA + VIRTUAL and submit today

Submission Period: April 14 - June 17, 2021, 6:00 P.M. CDT/UTC-5
Become a Member Now

General Information

- The American Heart Association’s Scientific Sessions 2021 is a forum for presentation of novel research findings.
  - The work covered by the abstract must not have been presented at a national or international meeting before presentation at Scientific Sessions 2021 (Nov. 13-15, 2021, in print or electronically).
  - Abstracts associated with a published manuscript can be presented at an AHA scientific event if the manuscript was published after the time the abstract was submitted to the event, however the abstract will not be published as a part of the journal publication.
  - There is a non-refundable submission fee for each abstract submitted. The fee covers administration and online costs associated with the submission, grading, notification and slotting processes.

  - **Submission Fee Pricing**
    - Standard Abstract Fee Pricing: Member $49/Non-member $99
    - World Bank Abstract Fee Pricing $15
    - (Please check the LMIC list for your country)

- To ensure that your abstract is considered for the appropriate meeting, please select from the appropriate category options.
  - Abstract Categories:
    - [Scientific Sessions](#) - Be sure to select the appropriate category in one of the three multidisciplinary science types.
    - [Resuscitation Science Symposium (ReSS)](#)
    - [Quality of Care and Outcomes Research (QCOR)](#)

- After the June 10, 2021, 6:00 PM CDT/UTC-5 submission deadline, abstracts are no longer accessible and therefore may not be revised in any way or resubmitted. Proofread abstracts carefully to avoid errors before the submission deadline. If accepted, your abstract will be published as submitted; it is not edited.
Abstract acceptance/non-acceptance status will be available by mid-August. Please ensure that the email provided for the presenting author is accurate as all correspondences will be sent via email, to the presenting author.

Please make sure your e-mail settings will allow e-mails from AHAScientificSessions@abstractmanagement.com to ensure important program participant related information to get through your spam filters, etc.

Abstract Copyright Transfer Agreement will be electronically signed during submission. Your selection of “Yes” grants permission to publish. Your selection of “No” prohibits publication of abstract.

Accepted abstracts having selected “Yes” to the Copyright Transfer Agreement will be published as they were submitted (ie, they will not be edited). They will appear in an online-only supplement to Circulation, an American Heart Association journal as well as the online Program Planner, Mobile Meeting Guide, Abstracts on USB and ePosters.

The presenting author of an accepted abstract must register and pay the registration fee for the meeting. Abstract presenters need to register in the appropriate category (eg, AHA member, nonmember) and pay the appropriate registration fees under each category.

All expenses (eg, airfare, lodging, conference registration) associated with the submission and presentation of an abstract are the responsibility of the presenter.

All accepted abstracts will be scheduled either in an oral or poster presentation. All presentations including question-and-answers will be conducted in English. Presenters may request assistance from the moderator who will repeat or rephrase questions from the audience or may ask a colleague in the audience to assist with translation.

For questions regarding the submission guidelines, please contact AHAScientificAbstracts@heart.org to reach an AHA programming staff member.

Abstract Grading

Abstracts successfully submitted by the June 17, 2021, 6:00 pm CDT/UTC -5 deadline are posted to a secured web site for blinded review. Our intent is to be most inclusive of the quality science received without compromising scientific integrity. As such, a team of 8 to 10 experts, selected by the Committee for Scientific Sessions Program, independently reviews abstracts in their category that best fits their expertise. Abstracts submitted for consideration must be an original idea, concept, or an
improvement or revision of a previous idea. Abstracts are selected on the basis for the following:

- **Scientific Merit** - direction toward the development of a new or improved diagnostic procedure or idea.
- **Organization** - well organized, easy to follow and understand.
- **Practicality** - should be available, logical, and feasible.
- **Presentation** - should be clear, brief, show understanding of the subject matter.
- **Technical quality** - the idea must stand up to scrutiny. Facts and data have scientific backing.

**Rules for Submitting an Abstract**

- All abstracts must be submitted in English with accurate grammar and spelling suitable for publication.

- The work covered by the abstract must not have been presented at a national or international meeting before presentation at Scientific Sessions 2021 (Nov. 13-15, 2021, in print or electronically).

- Abstracts associated with a published manuscript can be presented at an AHA scientific event if the manuscript was published after the time the abstract was submitted to the event, however the abstract will not be published as a part of the journal publication.

- If the abstract is submitted to more than one meeting, investigators must include significant new and scientifically meaningful information at time of submission to the AHA.

- If identical abstracts are accepted at two meetings, then one must be withdrawn and AHA staff must be notified. If acceptance of a previously presented abstract is discovered prior to presentation, it will be withdrawn and acceptance of future abstracts will be jeopardized. If dual presentation of identical abstracts is discovered after presentation, the acceptance of future abstracts may be jeopardized, and any award associated with the abstract will be withdrawn.

- Submission of an abstract constitutes a commitment by the author(s) to present it if accepted. Failure to present, if not justified, will jeopardize future acceptance of abstracts for the American Heart Association’s meetings/conferences.
• There is no limit to the number of abstracts an investigator may submit. If selected, the presenter must be one of the co-authors listed. If multiple submissions are accepted, if there are schedule conflicts, the presenting author must arrange for a co-author to present. Due to the number of abstracts being presented, abstracts cannot be moved to a different timeslot.

Embargo Policy

Non-latebreaking abstracts and presentations are embargoed for release at 5 a.m. ET, Monday, Nov. 8, 2021 and are therefore prohibited from release until date and time of AHA designated embargo time. For most abstracts, that embargo will be date and time of presentation but for some, the embargo will be the time of a specific AHA news media event. You will be contacted by AHA communications if you are selected to participate in an AHA news event.

Further, written embargoed information cannot be share with anyone outside of AHA with the exception of journal manuscript submission but you can conduct one-on-one embargoed media interviews as long as the reporter agrees to abide by the embargo policy. Failure to honor embargo policies will result in this abstract being withdrawn and future abstracts also being barred from presentation.

Preparing an Abstract

Abstract Title
An abstract must have a short, specific title (containing no abbreviations) that indicates the nature of the investigation.

Author Name(s)
• The submitting author is designated as the primary and presenting author. You may rearrange the order of the authors (during the submission period); however, always list the senior author last. The presenting author does not have to be listed as primary; the presenting author can be listed anywhere in the author block.
• If an author’s name appears on more than one abstract, it must be identical on each abstract.
• All authors’ names should be carefully reviewed for accuracy. If the abstract is accepted and eventually published, changes cannot be made after publication.
• Please review the author block carefully. Edits cannot be made once submission is complete. Author block will be printed as shown below. Additions or deletions of author names are not permitted after the submission deadline. NO EXCEPTIONS.

Abstract Data
• All abstracts must be submitted (and if accepted, will be presented) in English with accurate grammar and spelling suitable for publication.
• Authors should not "split" data to create several abstracts from one. If splitting is judged to have occurred, prior scores of related abstracts will be reduced.
• Abstracts containing identical or nearly identical data submitted from the same institution and/or individuals will be disqualified.
• Proofread abstracts carefully to avoid errors before the submission deadline. The abstract will be published exactly as it has been submitted – NO EXCEPTIONS.

Abstract Text
• Abstracts may have the following identifiable sections: Introduction, Hypothesis, Methods, Results and Conclusions. These fields can be edited or deleted as appropriate for your abstract.
• Describe briefly the objectives of the study unless they are contained in the title. Include a brief statement of methods if pertinent. State findings in detail sufficient to support conclusions. Abstracts should not describe research in which the chemical identity or source of the reagent is proprietary or cannot be revealed.
• Use generic drug names.
• Do not begin sentences with numerals.
• Standard abbreviations may be used without definition. Nonstandard abbreviations (kept to a minimum) must be placed in parentheses after the first use of the word or phrase abbreviated.
• Do not include references, credits, or grant support.
• Do not include the names or personal information of any patient participating in the study or trial.
• Abstracts are limited to 1,950 characters (about 300-350 words). This includes the text plus any graphics, but not the title or authors. All graphics (figures) and text-based graphics (tables) should be provided as 72-300 dpi, pre-sized .gif, .jpg or .tif images only, with a maximum width of 440 pixels (no limit on length). Black-and-white digital images should be in grayscale mode. Color images should be saved in RGB color mode. Addition of an image whether a figure or a table deducts 250 characters. Spaces do not count as characters.
• If an abstract is accepted for publication, any images submitted with the abstract are placed after the abstract that will appear in the online-only supplement to Circulation, an American Heart Association journal.

Abstract Acceptance

• Guidelines for abstract presentation will be provided to the presenting author of accepted abstracts in mid-August via email.
• All oral presentations must be in electronic slide form and submitted to the American Heart Association, we encourage use of the Scientific Sessions Slide Template, the template will be available by mid-October. If your abstract is
accepted for oral presentation, instructions to prepare and upload your presentation(s) will be emailed later in the fall.

- No person may record any portion of the AHA Scientific Sessions, Scientific Conferences, and ASA International Stroke Conference, whether by video, still, or digital photography; audio; or any other recording or reproduction mechanism. This includes recording of presentations and supporting A/V materials and of poster presentations and supporting poster materials.

Additionally, science information shared by investigators at the time of a meeting is confidential and often unpublished data. Taking photos of or recording the content of meeting room slides is also prohibited, and is considered intellectual piracy and unethical. Attendees who ignore this policy will be asked to leave the educational session and are at risk of losing their badge credentials.

- The American Heart Association and American Stroke Association reserve the rights to all recordings or reproductions of presentations at AHA/ASA scientific conferences and meetings.

- The AHA reserves the right to all video or audio recordings of presentations at Scientific Sessions 2021.